Lilly and foghorn announce strategic collaboration for novel oncology targets using foghorn's proprietary gene traffic control® platform

Indianapolis and cambridge, mass. , dec. 13, 2021 /prnewswire/ -- loxo oncology at lilly, a research and development group of eli lilly and company (nyse: lly), and foghorn therapeutics inc. (nasdaq: fhtx), today announced a strategic collaboration to create novel oncology medicines by applying foghorn's proprietary gene traffic control ® platform.
FHTX Ratings Summary
FHTX Quant Ranking